Rapamycin (sirolimus) is an FDA-approved immunosuppressant with the most robust evidence base of any drug for extending lifespan in mammalian models. The 2009 Harrison et al. Nature paper from the Interventions Testing Program (ITP) — the gold-standard multi-site aging intervention program funded by the NIA — showed that rapamycin feeding beginning at 600 days of age (roughly equivalent to starting at age 60 in humans) extended median lifespan by 9% in males and 14% in females in genetically heterogeneous mice. This was a landmark finding because it demonstrated that a pharmacological intervention could extend lifespan even when started in old age, suggesting effects on the aging process itself rather than simply prevention of a specific disease.
The target of rapamycin — mTORC1 (mechanistic target of rapamycin complex 1) — is now recognized as the central hub of cellular nutrient sensing, growth, and aging. When nutrients are abundant, mTORC1 is active: it drives protein synthesis, cell growth, and suppresses autophagy (the cellular recycling process). Chronic mTORC1 hyperactivity in aging contributes to cellular senescence, inflammation, and age-related disease. Rapamycin partially inhibits mTORC1, mimicking some effects of caloric restriction at the molecular level — the best-established longevity intervention across model organisms.
| Study | Model | Finding | Key Caveat |
|---|---|---|---|
| Harrison 2009 (ITP) | Mice, late-start 600 days | +9–14% median lifespan; multi-site replicated | Mouse lifespan ≠ human longevity; inbred vs heterogeneous differences |
| ITP dose escalation | Mice, 42ppm vs 14ppm | Higher dose → larger lifespan extension; dose-response confirmed | Higher dose = more immunosuppression; cataract risk in some strains |
| Mannick 2014 | N=218 healthy elderly humans | Improved flu vaccine response; reduced T cell exhaustion markers | 6-week treatment; biomarker endpoints ≠ longevity confirmed |
| Mannick 2018 | N=264 healthy elderly humans | RTB101 → -40% respiratory illness incidence in elderly | RTB101 ≠ rapamycin; different pharmacokinetics and receptor binding |
| PEARL (ongoing) | N=300 healthy humans 50–85 | 5mg rapamycin weekly; results 2025–2026 | Powered for safety/biomarkers, not lifespan; will define field direction |
| Rapa + metformin (ITP) | Mice | Additive lifespan benefit beyond either drug alone (Albers 2021) | No human combination trial; theoretical synergy unvalidated in humans |
Who is using it off-label: A growing number of longevity physicians prescribe rapamycin at 2–6mg weekly or biweekly for healthy aging-focused adults, typically starting around age 50; estimated 10,000–20,000 people in the US are using rapamycin off-label for longevity as of 2026; the weekly pulse dosing rationale: achieves transient mTORC1 inhibition while allowing mTORC2 to recover between doses, avoiding insulin resistance and dyslipidemia seen with chronic daily transplant dosing; this is biologically rational but not RCT-validated in humans.
The honest uncertainty: We do not know whether mouse lifespan data translates to human longevity; we do not know the long-term safety of low-dose intermittent rapamycin in healthy humans; the PEARL trial is powered for safety and biomarkers, not lifespan; unlike GLP-1s (where multi-year cardiovascular outcomes RCT data exists), rapamycin longevity use operates at the frontier of evidence. The physicians prescribing it are making reasoned bets based on animal data and mechanism, not established human evidence.
Natural mTOR modulation (no prescription needed): Caloric restriction (strongest animal data; less clear in humans at realistic restriction levels); time-restricted eating / intermittent fasting (reduces daily mTOR activation cycle); Zone 2 exercise (AMPK activation cross-inhibits mTOR); adequate sleep (mTOR activity highest during wakefulness, attenuated during sleep); protein cycling (periodic lower protein intake reduces mTOR signaling — rationale for protein-restricted days in longevity protocols); berberine (AMPK activator with modest mTOR cross-inhibition, 500mg 2–3×/day, available without prescription). These are not as potent as pharmacological rapamycin but carry no adverse effects and have broad independent evidence.
Contraindications to off-label rapamycin: Active infection; planned surgery within 4–6 weeks (impairs wound healing); pregnancy; immunocompromise from any cause; concurrent CYP3A4 inhibitors (azole antifungals, macrolide antibiotics dramatically increase rapamycin blood levels); anyone considering off-label use should work with a physician monitoring CBC, lipids, fasting glucose, and kidney function every 3–6 months.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.